Schmitt V, Rodríguez-Rodríguez C, Hamilton J L, Shenoi R A, Schaffer P, Sossi V, Kizhakkedathu J N, Saatchi K, Häfeli U O
The University of British Columbia, Faculty of Pharmaceutical Sciences 2405 Wesbrook Mall Vancouver BC V6T1Z3 Canada
Department of Physics & Astronomy, The University of British Columbia Vancouver BC Canada.
RSC Adv. 2018 Feb 1;8(10):5586-5595. doi: 10.1039/c7ra09183d. eCollection 2018 Jan 29.
Polymeric nanocarriers are promising entities for cancer diagnosis and therapy. The aim of such nanocarriers is to selectively accumulate in cancerous tissue that is difficult to visualize or treat. The passive accumulation of a nanocarrier in a tumor through extravasation is often attributed to the enhanced permeation and retention (EPR) effect and the size and shape of the nanocarrier. However, the tumor microenvironment is very heterogeneous and the intratumoral pressure is usually high, leading to different opinions about how the EPR of nanocarriers through the irregular vasculature of a tumor leads to accumulation. In order to investigate this topic, we studied methods for the determination of pharmacokinetic parameters, biodistribution and the tumor uptake of nanocarriers. More specifically, we used non-invasive quantitative Single-Photon Emission Computed Tomography/Computed Tomography (qSPECT/CT) imaging of hyperbranched polyglycerols (HPGs) to explore the specific biodistribution and tumor uptake of six model nanocarriers in Rag2m mice. We were interested to see if a distinct molecular weight (MW) of nanocarriers (HPG 25, 50, 100, 200, 300, 500 kDa) is favoured by the tumor. To trace the model nanocarriers, HPGs were covalently linked to the strong chelator desferrioxamine (DFO), and radiolabeled with the gamma emitter Ga (EC = 100%, = 185 keV (21.4%), 300 keV (16.6%), half-life = 3.26 d). Without the need for blood collection, but instead using qSPECT/CT imaging inside the heart, the blood circulation half-lives of the Ga labeled HPGs were determined and increased from 9.9 ± 2.9 to 47.8 ± 7.9 hours with increasing polymer MW. Total tumor accumulation correlated positively with the circulation time of the HPGs. Comparing the tumor-to-blood ratio dynamically revealed how blood and tumor concentrations of the nanocarrier change over time and when equilibrium is reached. The time of equilibrium is size-dependent and increases with molecular weight. Furthermore, the data indicate that for larger MWs, nanocarrier uptake and retention by the tumor is size independent. Further studies are necessary to advance our understanding of the interplay between MW and nanoparticle accumulation in tumors.
聚合物纳米载体是癌症诊断和治疗中有前景的实体。此类纳米载体的目标是选择性地在难以可视化或治疗的癌组织中蓄积。纳米载体通过血管外渗在肿瘤中的被动蓄积通常归因于增强的渗透和滞留(EPR)效应以及纳米载体的大小和形状。然而,肿瘤微环境非常异质性,肿瘤内压力通常较高,这导致对于纳米载体通过肿瘤不规则脉管系统的EPR如何导致蓄积存在不同观点。为了研究这个主题,我们研究了测定纳米载体药代动力学参数、生物分布和肿瘤摄取的方法。更具体地说,我们使用超支化聚甘油(HPG)的非侵入性定量单光子发射计算机断层扫描/计算机断层扫描(qSPECT/CT)成像来探索六种模型纳米载体在Rag2m小鼠中的特定生物分布和肿瘤摄取。我们感兴趣的是看看纳米载体(HPG 25、50、100、200、300、500 kDa)的不同分子量(MW)是否受肿瘤青睐。为了追踪模型纳米载体,将HPG与强螯合剂去铁胺(DFO)共价连接,并用γ发射体Ga进行放射性标记(电子俘获 = 100%, = 185 keV(21.4%),300 keV(16.6%),半衰期 = 3.26天)。无需采血,而是利用心脏内部的qSPECT/CT成像,测定了Ga标记的HPG的血液循环半衰期,并且随着聚合物MW的增加,半衰期从9.9±2.9小时增加到47.8±7.9小时。肿瘤总蓄积与HPG的循环时间呈正相关。动态比较肿瘤与血液的比率揭示了纳米载体的血液和肿瘤浓度如何随时间变化以及何时达到平衡。平衡时间取决于大小,并随分子量增加。此外,数据表明,对于较大的MW,肿瘤对纳米载体的摄取和滞留与大小无关。需要进一步研究以加深我们对MW与纳米颗粒在肿瘤中蓄积之间相互作用的理解。